Abbott Reports (MONITOR-HF) Trial Results of CardioMEMS Sensor for the Treatment of Heart Failure
Shots:
- The company presented the data at ESC 2023 & published in The Lancet from an investigator-sponsored EU (MONITOR-HF) trial evaluating the CardioMEMS HF system in 348 patients at 25 centers in the Netherlands
- The trial met its 1EPs & showed a clinical improvement in QoL as quantified by a 7-point mean increase in KCCQ score vs the control group who did not receive the pressure sensor & whose scores decreased as early as 3mos. after use with a remote monitoring sensor
- 44% reduction in HF-related hospitalizations for those who used guideline-directed medical therapy & showed health benefits. CardioMEMS, a paperclip-sized sensor that can remotely flag to a patient's clinical team the early warning signs of worsening HF
Ref: PR Newswire | Image: Abbott
Related News:- Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
